10 Companies Applying AI for Biologics Discovery
When we hear “AI in drug discovery”, there is a high chance our imagination would draw a small molecule discovery in the first place. Indeed, as it was captured and analyzed in the report The Landscape of Artificial Intelligence (AI) In Pharmaceutical R&D roughly half of more than 300 analyzed AI-driven companies focus on small molecules as a therapeutic modality. This biggest category is then followed by smaller groups of biologics, biomarkers and therapies as an R&D focus. The success of small molecule discovery coupled with AI already demonstrates performance with some “AI-inspired” drug candidates entering the clinical trials, like Relay Therapeutics with their precision oncology small molecules in clinical trials for previously ‘undruggable’ targets, or Exscientia with their small molecule candidate to treat obsessive-compulsive disorder, which began human testing in a phase I trial in 2020 in collaboration with Sumitomo Dainippon Pharma.
Topics: AI & Digital